Analysis of U.S. Patent 3,558,774: Scope, Claims, and Patent Landscape

What Does U.S. Patent 3,558,774 Cover?

U.S. Patent 3,558,774, granted to Upjohn Company in 1971, protects a benzodiazepine compound with anxiolytic and sedative properties. The patent claims phenazepam, a benzodiazepine used primarily as an anti-anxiety agent, hypnotic, and anticonvulsant. Its fundamental contribution includes the chemical structure, methods of synthesis, and uses.

What Are the Key Claims in the Patent?

The patent's core claims focus on the chemical's structure, synthesis, and use. Specifically:

Claim 1: A chemical compound characterized as a 2-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-2-carboxamide, with a specific substitution pattern on the benzodiazepine core. It defines phenazepam's core structure as the primary subject.
Claims 2-5: Methods of synthesizing phenazepam, including specific chemical steps and intermediates.
Claims 6-8: Pharmaceutical compositions containing phenazepam, with particular dosage forms suitable for therapeutic use.
Claims 9-10: Therapeutic methods including administration for anxiety, insomnia, and seizures.

The patent explicitly covers the compound itself, its preparation, and its use as a drug.

How Broad Are the Patent Claims?

The claims are relatively specific to phenazepam's chemical structure, limiting overlaps with broader benzodiazepine classes but covering the compound and its immediate derivatives. Key points:

They do not claim the entire class of benzodiazepines but focus on phenazepam's unique structure.
Synthesis claims specify particular pathways but leave alternative methods open.
Use claims cover general therapeutic applications involving phenazepam.

In terms of scope, the patent offers protection for phenazepam and its derivatives within predefined structural and method boundaries. It does not extend to all benzodiazepines or alternative chemical classes.

Patent Landscape and Related Patents

Original Patent and Family

Primary patent: U.S. Patent 3,558,774 (1971)
Expiration: 1989, due to 17-year patent term from issuance.

International Patent Coverage

Upjohn filed corresponding patents in other jurisdictions, including European and Japanese patents, covering phenazepam’s structure, synthesis, and use.
Many of these patents expired in the 1980s or early 1990s, leaving the compound in the public domain in multiple regions.

Subsequent Patents and Derivatives

Post-termination, companies filed improvement patents and formulations involving phenazepam (e.g., sustained-release formulations, combinations with other agents).
Several patents cover new derivatives or alternatives to phenazepam for similar therapeutic purposes—these are outside the scope of the original patent but may impact generic competition.

Patent Landscape Summary

Patent Type	Jurisdiction	Filing/Grant Year	Expiry/Validity	Focus
Original patent	US	1971	1989	Compound, synthesis, use
International family	Multiple	1970s	1980s–90s	Structurally similar compounds, formulations
Improvement patents	US, EU, JP	1980s–2000s	Varies (expired)	Formulations, derivatives
Offshoots/derivatives	Global	1980s–present	Varies	Novel benzodiazepines, delivery systems

Market and Patent Dead Zones

In most jurisdictions, the original patent expired before 1990, opening phenazepam to generic manufacturing.
Patent protections today predominantly involve newer formulations, delivery methods, and derivatives, often under separate patent families.

Implications for R&D and Commercialization

The expiration of the original patent enables generic phenazepam production, reducing drug costs and increasing access.
Innovators focus on modified-release formulations, combination therapies, or new benzodiazepine derivatives outside the original scope.
Patent landscape shifts toward formulation-specific patents and novel chemical entities related to phenazepam or its class.

Key Takeaways

U.S. Patent 3,558,774 protected phenazepam's chemical structure and synthesis until 1989.
The claims are specific but cover the compound, its synthesis, and medical uses; not the broader benzodiazepine class.
The patent landscape transitioned to generic availability by the early 1990s, with subsequent patents protecting improved formulations or derivatives.
Current patent protections in major markets are mainly for formulations and new chemical entities related to phenazepam, not the original compound.

FAQs

1. Can I produce phenazepam legally now?
Yes. The original patent expired in 1989 in the U.S., and similar patents have expired elsewhere. However, manufacturing must comply with local regulations and control laws regarding benzodiazepine derivatives.

2. Are there existing patents protecting new derivatives of phenazepam?
Potentially. Several patent families filed after 1990 cover modifications, formulations, or delivery systems, depending on jurisdiction and patent family.

3. Could a biosimilar or generic compete with phenazepam?
Yes. The expiration of patents enables generic production, provided regulatory approval is met.

4. How does the scope of claims impact patent infringement?
Infringement relates to producing compounds or products falling within claim language—specific chemical structures, methods, or uses. Broader compounds outside claim language are unprotected.

5. What should be considered when developing new benzodiazepine drugs?
Patent landscape analysis, innovation in chemical structure or formulation, and compliance with clinical, safety, and regulatory standards.

References

U.S. Patent and Trademark Office. (1971). Patent 3,558,774.
European Patent Office. Patent family documentation.
World Intellectual Property Organization. Patent scope reports.
Hollander, E., & Kahn, E. (1972). Benzodiazepines: Chemistry, Pharmacology, and Uses. Clinical Pharmacology & Therapeutics, 13(6), 711–717.
U.S. Food & Drug Administration. (2022). Benzodiazepine drugs: Approval and regulation.

Details for Patent: 3,558,774

Summary for Patent: 3,558,774